Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

FBTCX Fidelity Advisor® Biotechnology C

  • Fund
  • FBTCX
  • Price as of: Jul 15, 2019
  • $22.25 + $0.14 + 0.63%
  • Category
  • Health & Biotech Equities

FBTCX - Profile

Vitals

  • YTD Return 10.1%
  • 3 Yr Annualized Return 7.9%
  • 5 Yr Annualized Return 5.5%
  • Net Assets $2.3 B
  • Holdings in Top 10 60.7%

52 WEEK LOW AND HIGH

$22.25
$18.57
$25.02

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.80%

SALES FEES

  • Front Load N/A
  • Deferred Load 1.00%

BROKERAGE FEES

  • Turnover 45.00%

TRADING FEES

  • Max Redemption Fee 0.75%

Min Investment

STANDARD (TAXABLE)

$0

IRA

$500

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 10.1%
  • 3 Yr Annualized Total Return 7.9%
  • 5 Yr Annualized Total Return 7.3%
  • Capital Gain Distribution Frequency Semi-Annually
  • Net Income Ratio -1.27%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency None

Fund Details

  • Legal Name Fidelity Advisor® Biotechnology Fund
  • Fund Family Name Fidelity Investments
  • Inception Date Dec 27, 2000
  • Shares Outstanding N/A
  • Share Class C
  • Currency USD
  • Domiciled Country United States
  • Manager Eirene Kontopoulos

Fund Description

The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments. The fund is non-diversified.

FBTCX - Performance

Return Ranking - Trailing

Period FBTCX Return Category Return Low Category Return High Rank in Category (%)
YTD 10.1% -3.0% 33.2% 50.98%
1 Yr -10.2% -24.9% 12.0% 74.51%
3 Yr 7.9%* -17.8% 22.2% 24.51%
5 Yr 5.5%* -11.9% 16.9% 21.43%
10 Yr 14.2%* -1.8% 16.1% 4.94%

* Annualized


Return Ranking - Calendar

Period FBTCX Return Category Return Low Category Return High Rank in Category (%)
2018 -7.0% -25.3% 7.7% 41.18%
2017 24.8% -10.8% 43.9% 17.65%
2016 -24.1% -29.8% 2.6% 91.18%
2015 4.7% -20.4% 13.8% 13.73%
2014 29.6% -5.8% 31.5% 4.08%

Total Return Ranking - Trailing

Period FBTCX Return Category Return Low Category Return High Rank in Category (%)
YTD 10.1% -3.0% 33.2% 55.88%
1 Yr -10.2% -24.9% 12.0% 77.45%
3 Yr 7.9%* -17.8% 25.3% 33.33%
5 Yr 7.3%* -11.9% 18.8% 44.90%
10 Yr 16.0%* -1.8% 19.4% 18.52%

* Annualized


Total Return Ranking - Calendar

Period FBTCX Return Category Return Low Category Return High Rank in Category (%)
2018 -7.0% -25.3% 12.3% 50.98%
2017 24.8% -10.8% 45.8% 19.61%
2016 -24.1% -24.2% 8.7% 99.02%
2015 10.5% -16.6% 15.2% 21.57%
2014 33.4% -5.8% 36.7% 16.33%

NAV & Total Return History

FBTCX - Holdings

Concentration Analysis

FBTCX Category Low Category High FBTCX % Rank
Net Assets 2.3 B 13.9 M 44.3 B 30.39%
Number of Holdings 83 28 364 54.90%
Net Assets in Top 10 1.3 B 7.98 M 18.8 B 24.51%
Weighting of Top 10 60.73% 24.8% 75.2% 6.86%

Top 10 Holdings

  1. AbbVie Inc 11.09%

  2. Vertex Pharmaceuticals Inc 10.11%

  3. Celgene Corp 9.22%

  4. Alexion Pharmaceuticals Inc 8.74%

  5. Amgen Inc 7.35%

  6. Gilead Sciences Inc 4.59%

  7. Neurocrine Biosciences Inc 2.66%

  8. Ascendis Pharma A/S ADR 2.57%

  9. Sage Therapeutics Inc 2.24%

  10. Sarepta Therapeutics Inc 2.14%


Asset Allocation

Weighting Return Low Return High FBTCX % Rank
Stocks
98.59% 91.85% 103.82% 28.43%
Cash
1.02% 0.00% 5.75% 73.53%
Preferred Stocks
0.40% 0.00% 2.32% 11.76%
Other
0.00% -3.83% 2.75% 63.73%
Convertible Bonds
0.00% 0.00% 0.12% 53.92%
Bonds
0.00% 0.00% 0.94% 56.86%

Stock Sector Breakdown

Weighting Return Low Return High FBTCX % Rank
Healthcare
97.84% 13.80% 99.56% 13.73%
Utilities
0.00% 0.00% 0.00% 51.96%
Technology
0.00% 0.00% 61.10% 83.33%
Real Estate
0.00% 0.00% 1.36% 58.82%
Industrials
0.00% 0.00% 10.61% 70.59%
Financial Services
0.00% 0.00% 3.95% 61.76%
Energy
0.00% 0.00% 0.09% 51.96%
Communication Services
0.00% 0.00% 0.00% 51.96%
Consumer Defense
0.00% 0.00% 0.40% 57.84%
Consumer Cyclical
0.00% 0.00% 7.87% 61.76%
Basic Materials
0.00% 0.00% 0.79% 62.75%

Stock Geographic Breakdown

Weighting Return Low Return High FBTCX % Rank
US
95.51% 60.46% 99.56% 9.80%
Non US
3.08% 0.00% 39.02% 90.20%

FBTCX - Expenses

Operational Fees

FBTCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.80% 0.10% 2.98% 25.49%
Management Fee 0.54% 0.09% 1.25% 12.75%
12b-1 Fee 1.00% 0.00% 1.00% 88.41%
Administrative Fee N/A 0.01% 0.40% N/A

Sales Fees

FBTCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load 1.00% 1.00% 5.00% 70.83%

Trading Fees

FBTCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee 0.75% 0.75% 2.00% 90.00%

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBTCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 45.00% 0.00% 699.00% 65.69%

FBTCX - Distributions

Dividend Yield Analysis

FBTCX Category Low Category High FBTCX % Rank
Dividend Yield 0.00% 0.00% 0.01% 62.75%

Dividend Distribution Analysis

FBTCX Category Low Category High Category Mode
Dividend Distribution Frequency None Annually Annually Annually

Dividend Payout History


Net Income Ratio Analysis

FBTCX Category Low Category High FBTCX % Rank
Net Income Ratio -1.27% -2.15% 1.48% 90.20%

Capital Gain Distribution Analysis

FBTCX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Semi-Annually Annually Semi-Annually Annually

FBTCX - Managers

Eirene Kontopoulos

Manager

Start Date

Tenure

Tenure Rank

Jul 15, 2018

0.96

1.0%

Eirene Kontopoulos joined Fidelity Investments in 2007, she has worked as a research analyst and portfolio manager.


Tenure Analysis

Category Low

4.38

Category High

13.75

Category Average

9.07

Category Mode

4.38